ARCHIVES

PV-10 Produces 51 Percent Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

DCBD Board Rejects Breast Cancer Multiple Markers Concept Proposal

November 4, 1983

DeVita Appointment Now Official; Calls For New Chemoprevention Program, More Applied Prevention

July 18, 1980

Final Issue of the Year

December 13, 1985

ORI Instructs NSAB to Prepare for Investigation

April 19, 1996

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Senate Votes To Invalidate Task Force Guideline

December 4, 2009